Daniel Espinosa
Family Medicine · Victoria, TXNPI 1235585381
Payments from drug & device makers
Across 131 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$536
- AstraZeneca$510
- Lilly USA, LLC$310
- Exact Sciences$154
- Amgen$137
- Astellas Pharma US Inc$136
- plus $691 from 17 others
What the payments were for
- Food & beverage$2,36195%
- Education$1145%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $536 |
| AstraZeneca | 28 | $510 |
| Lilly USA, LLC | 18 | $310 |
| Exact Sciences | 8 | $154 |
| Amgen | 8 | $137 |
| Astellas Pharma US Inc | 3 | $136 |
| Bayer | 6 | $114 |
| GSK | 6 | $96 |
| Pfizer | 5 | $88 |
| Nevro Corp. | 2 | $74 |
| Shield Therapeutics Inc | 3 | $53 |
| Boehringer Ingelheim | 2 | $32 |
| Urogen Pharma, Inc. | 1 | $30 |
| Merck | 2 | $29 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
How this compares
$2,475 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $184,807 |
| MounjaroTirzepatide | 114 | $130,790 |
| FarxigaDapagliflozin Propanediol | 117 | $126,470 |
| EliquisApixaban | 71 | $67,563 |
| RybelsusSemaglutide | 28 | $50,784 |
| JanuviaSitagliptin Phosphate | 31 | $33,870 |
| MyrbetriqMirabegron | 31 | $32,028 |
| XareltoRivaroxaban | 20 | $27,708 |
| TrulicityDulaglutide | 17 | $25,808 |
| JardianceEmpagliflozin | 23 | $24,242 |
| LinzessLinaclotide | 16 | $20,338 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $14,645 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,177 |
| SynjardyEmpagliflozin/Metformin Hcl | 20 | $6,542 |
| Levemir FlexpenInsulin Detemir | 39 | $6,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $536 | $235,591158 claims |
| Lilly USA, LLCMounjaro, Trulicity | $310 | $156,598131 claims |
| AstraZenecaFarxiga, Symbicort | $510 | $134,647144 claims |
| PfizerEliquis | $88 | $67,56371 claims |
| MerckJanuvia, Janumet | $29 | $40,04442 claims |
| Astellas Pharma US IncMyrbetriq | $136 | $32,02831 claims |
| Boehringer IngelheimJardiance, Synjardy | $32 | $30,78343 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $25 | $2,706177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Victoria
- Richard LeggettVictoria$7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.